why gbi will deliver 10x returns over 12 mths, page-6

June 2009 looks like they will have CE Mark and TGA approval for PapType...if they can't trade sale the asset for US$75 to US$100m then there's something wrong....check out Compco acquisition prices (Digene US$1.6bn AUg 2007, Innogenetics $316m Euro July 2008, Thirdwave Technologies US$580m June 2008 and recent CMED acquisition US$345m Oct 2008)...there isn't much prospective real estate left in this area globally and all the incumbents have got taken out via all CASH bids at VERY reasonable prices...GBI has a WEHI pedigree (ie. Amgen EPO like) with close Sonic Healthcare ties...an investment banker's trade sale mandate dream in this market!

51.2m shares on issue